↓ Skip to main content

Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2)

Overview of attention for article published in Investigational New Drugs, October 2019
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
26 Mendeley
Title
Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2)
Published in
Investigational New Drugs, October 2019
DOI 10.1007/s10637-019-00857-6
Pubmed ID
Authors

Ruud van der Noll, Agnes Jager, Joo Ern Ang, Serena Marchetti, Marja W. J. Mergui-Roelvink, Johann S. de Bono, Martijn P. Lolkema, Maja J. A. de Jonge, Diane A. van der Biessen, Andre T. Brunetto, Hendrik-Tobias Arkenau, Ilian Tchakov, Jos H. Beijnen, Jacques De Grève, Jan H. M. Schellens

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 26 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 3 12%
Student > Bachelor 3 12%
Student > Ph. D. Student 2 8%
Librarian 1 4%
Professor > Associate Professor 1 4%
Other 0 0%
Unknown 16 62%
Readers by discipline Count As %
Medicine and Dentistry 4 15%
Computer Science 2 8%
Nursing and Health Professions 1 4%
Psychology 1 4%
Immunology and Microbiology 1 4%
Other 0 0%
Unknown 17 65%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 January 2021.
All research outputs
#18,695,869
of 23,170,347 outputs
Outputs from Investigational New Drugs
#883
of 1,179 outputs
Outputs of similar age
#265,985
of 357,172 outputs
Outputs of similar age from Investigational New Drugs
#4
of 10 outputs
Altmetric has tracked 23,170,347 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,179 research outputs from this source. They receive a mean Attention Score of 4.7. This one is in the 16th percentile – i.e., 16% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 357,172 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.